Skip to main content
Medicus Pharma Ltd. logo

Medicus Pharma Ltd. — Investor Relations & Filings

Ticker · MDCX ISIN · CA58471K2020 LEI · 984500563DE3E9558204 US Manufacturing
Open in API
Filings indexed 268 across all filing types
Latest filing 2026-06-04 Declaration of Voting R…
Country CA Canada
Listing US MDCX

About Medicus Pharma Ltd.

https://medicuspharma.com/

Medicus Pharma Ltd. is a biotechnology and life sciences company focused on accelerating the clinical development of novel and disruptive therapeutic assets. The company's primary focus is on developing non-invasive treatments for dermatological conditions, specifically non-melanoma skin cancers. Its lead therapeutic candidate, SKNJCT-003, is being developed by its subsidiary, SkinJect Inc., for the treatment of basal cell carcinoma (BCC). The candidate is currently in Phase 2 clinical studies. Medicus Pharma aims to deliver improved treatment outcomes through the development of first-in-class and best-in-class therapies.

Recent filings

Filing Released Lang Actions
FORM 424B3
Declaration of Voting Results & Voting Rights Announcements Classification · 88% confidence The document is a Form 424B3 prospectus supplement paired with a Form 8-K “Current Report” that primarily discloses Item 5.07 — the submission of matters to a vote of security holders at the 2026 Annual General and Special Meeting, with detailed vote counts on each proposal. This aligns exactly with the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-06-04 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a Form 8-K “Current Report” filed pursuant to the Securities Exchange Act, specifically Item 5.07 "Submission of Matters to a Vote of Security Holders." It lists the proposals voted at the 2026 Annual General and Special Meeting and the detailed vote tallies for each proposal. This corresponds to a declaration of shareholder vote results, matching Filing Definition “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-06-04 English
FORM 424B3
Regulatory Filings Classification · 86% confidence The document is an SEC filing comprising a prospectus supplement on Form 424B3 and an attached Form 8-K current report, updating the company’s offering and reporting material definitive agreements and Nasdaq compliance notice. This is not an earnings release, annual report, call transcript, or other specialized category but a general regulatory submission. Therefore, it falls under Regulatory Filings (RNS).
2026-05-27 English
FORM 8-K
Regulatory Filings Classification · 88% confidence The document is a Current Report on Form 8-K filed with the SEC on May 20, 2026. It discloses entry into a material note purchase agreement (capital/financing transaction under Item 2.03) and notice of Nasdaq non-compliance/delisting risk (Item 3.01), along with exhibits. It is not a full annual (10-K) or quarterly (10-Q/IR) report, nor a simple earnings release or proxy statement. As a multipurpose SEC current report covering regulatory events and disclosures, it best fits the generic “Regulatory Filings” category.
2026-05-27 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
FORM 424B3
Regulatory Filings
2026-05-14 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.